scispace - formally typeset
Open AccessJournal ArticleDOI

Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model.

Reads0
Chats0
TLDR
It is found that microglia, instead of tau-induced direct neurotoxicity, are the driving force of neurodegeneration in a tauopathy mouse model and apoE strongly regulates neurodegenersation in the setting of tAUopathy predominantly by modulating microglial function.
Abstract
Chronic activation of brain innate immunity is a prominent feature of Alzheimer's disease (AD) and primary tauopathies. However, to what degree innate immunity contributes to neurodegeneration as compared with pathological protein-induced neurotoxicity, and the requirement of a particular glial cell type in neurodegeneration, are still unclear. Here we demonstrate that microglia-mediated damage, rather than pathological tau-induced direct neurotoxicity, is the leading force driving neurodegeneration in a tauopathy mouse model. Importantly, the progression of ptau pathology is also driven by microglia. In addition, we found that APOE, the strongest genetic risk factor for AD, regulates neurodegeneration predominantly by modulating microglial activation, although a minor role of apoE in regulating ptau and insoluble tau formation independent of its immunomodulatory function was also identified. Our results suggest that therapeutic strategies targeting microglia may represent an effective approach to prevent disease progression in the setting of tauopathy.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Synergy between amyloid-β and tau in Alzheimer’s disease

TL;DR: Emerging evidence for an interaction between Aβ and tau during Alzheimer’s disease (AD) progression that challenges the classical linear trajectory model and offers a new perspective on AD pathophysiology and therapy is reviewed.
Journal ArticleDOI

APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches

TL;DR: Understanding of APOE pathogenesis has expanded beyond amyloid-β peptide-centric mechanisms to tau neurofibrillary degeneration, microglia and astrocyte responses, and blood-brain barrier disruption, and it is important to use this body of knowledge to develop therapies directed at APOE.
Journal ArticleDOI

Novel Alzheimer risk genes determine the microglia response to amyloid-β but not to TAU pathology.

TL;DR: It is concluded that genetic risk of AD functionally translates into different microglia pathway responses to Aβ pathology, placing AD genetic risk downstream of the amyloid pathway but upstream of TAU pathology.
Journal ArticleDOI

Microglia: Agents of the CNS Pro-Inflammatory Response

TL;DR: The phenotypic transformation from homeostatic microglia towards reactivemicroglia is discussed, initiated by specific ligand binding to pattern recognition receptors including toll-like receptor-4 (TLR4) or triggering receptors expressed on myeloid cells-2 (TREM2) as well as pro-inflammatory signaling pathways triggered such as the caspase-mediated immune response.
References
More filters
Journal ArticleDOI

Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease

TL;DR: The severity of dementia was positively related to the number of NFTs in neocortex, but not to the degree of SP deposition, and N FTs accumulate in a consistent pattern reflecting hierarchic vulnerability of individual cytoarchitectural fields.
Journal ArticleDOI

Colony-Stimulating Factor 1 Receptor Signaling Is Necessary for Microglia Viability, Unmasking a Microglia Progenitor Cell in the Adult Brain

TL;DR: Surprisingly, extensive treatment results in elimination of ∼99% of all microglia brain-wide, showing that microglian homeostasis in the adult brain are physiologically dependent upon CSF1R signaling.
Related Papers (5)